Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)

Overview of attention for article published in Arthritis Research & Therapy, March 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

facebook: 2 Facebook pages

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 2 public wall posts from 2 users.

Angels Sharing Scleroderma Awareness, 08 Mar 2021

Lupus in the News: A recent clinical trial (phase 11a) has demonstrated that low doses of the leukemia drug, arsenic trioxide (AT…

New England Fitchburg Lupus Walk, 08 Mar 2021

Lupus in the News: A recent clinical trial (phase 11a) has demonstrated that low doses of the leukemia drug, arsenic trioxide (AT…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.